A UK-qualified physician, Dr Eisen has 24 years’ experience in regulation and the pharmaceutical industry.
He has worked in senior positions as a UK and EU drug regulator, and from 2006–2011 was Chief Medical Officer at Teva Pharmaceuticals Europe.
His experience of regulatory and drug development issues will assist Phosphate Therapeutics in its current development of renal drug PT20 towards clinical trials.
PT20, developed through an exclusive agreement with Shield Therapeutics, is a novel phosphate binder to treat the severe excess of blood phosphates associated with end-stage renal failure.
The drug was licensed from MRC Technology, the technology transfer company of the Medical Research Council, and its development is funded by life science venture capital investor Inventages.
Carl Sterritt, CEO of Phosphate Therapeutics, said: “I am delighted to see Sandy joining the Board of Phosphate Therapeutics. I am sure his wealth of experience in new drug and new biological applications, clinical trials and drug safety will prove most valuable to the ongoing development of PT20, our lead asset.”
“PT20 has shown significant therapeutic promise in early studies and has received considerable backing to complete Phase 2 development,” commented Dr Eisen. “I look forward to working with this experienced team as we work towards bringing PT20 to the market in the shortest possible time.”